Literature DB >> 7541848

Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.

R B Roden1, N L Hubbert, R Kirnbauer, F Breitburd, D R Lowy, J T Schiller.   

Abstract

Virus-like particles (VLPs) composed of L1 derived from bovine papillomavirus type 1 (BPV-1), several human papillomavirus types, or cottontail rabbit papillomavirus (CRPV) agglutinated mouse but not human or rat erythrocytes. Treatment of mouse erythrocytes with trypsin prevented hemagglutination (HA) by BPV-1. Sera from rabbits immunized with native CRPV VLPs, which protect against experimental CRPV infection, exhibited high titers of antibodies that inhibited CRPV VLP HA activity, while sera from rabbits immunized with denatured CRPV VLPs or native BPV VLPs, which do not protect against CRPV infection, were not inhibitory. Testing for HA inhibition is a rapid and simple method for examining the serological relatedness of papillomaviruses and measuring protective antibody titers after VLP vaccination.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7541848      PMCID： PMC189336     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  24 in total

1.  Studies on the virus of rabbit papilloma. 1. Methods of assay.

Authors:  D O WHITE; R J HUEBNER; W P ROWE; R TRAUB
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

Review 2.  Viral receptors of the immunoglobulin superfamily.

Authors:  J M White; D R Littman
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

3.  Proteins present in bovine papillomavirus particles.

Authors:  P M Larsen; L Storgaard; S J Fey
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

4.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.

Authors:  T S Baker; W W Newcomb; N H Olson; L M Cowsert; C Olson; J C Brown
Journal:  Biophys J       Date:  1991-12       Impact factor: 4.033

5.  Studies with human papilloma virus modeled after known papovavirus systems.

Authors:  J S Butel
Journal:  J Natl Cancer Inst       Date:  1972-02       Impact factor: 13.506

6.  Polyoma virus recognizes specific sialyligosaccharide receptors on host cells.

Authors:  H Fried; L D Cahan; J C Paulson
Journal:  Virology       Date:  1981-02       Impact factor: 3.616

7.  A quantitative in vitro focus assay for bovine papilloma virus.

Authors:  I Dvoretzky; R Shober; S K Chattopadhyay; D R Lowy
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

8.  Antibody-mediated neutralization in vivo of infectious papillomaviruses.

Authors:  N D Christensen; J W Kreider
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

Authors:  S Ghim; N D Christensen; J W Kreider; A B Jenson
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

10.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid.

Authors:  W Weis; J H Brown; S Cusack; J C Paulson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962
View more
  20 in total

1.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

Review 4.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

5.  Development of chimeric candidate vaccine against HPV18: a proof of concept.

Authors:  Mohammed Wahiduzzaman; Chandresh Sharma; Bindu Dey; Neerja Bhatla; Neeta Singh
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

6.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

7.  In vitro gene transfer using human papillomavirus-like particles.

Authors:  A Touze; P Coursaget
Journal:  Nucleic Acids Res       Date:  1998-03-01       Impact factor: 16.971

8.  Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.

Authors:  K Jyotsna Reddy; Babak Banapour; David E Anderson; Sang H Lee; Juan P Marquez; Maria P Carlos; Jose V Torres
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

9.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; N D Christensen; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 10.  Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.

Authors:  Balasubramanyam Karanam; Subhashini Jagu; Warner K Huh; Richard B S Roden
Journal:  Immunol Cell Biol       Date:  2009 May-Jun       Impact factor: 5.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.